In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China

Zhao, Chunjiang; Wang, Xiaojuan; Zhang, Yawei; Wang, Ruobing; Wang, Qi; Li, Henan; Wang, Hui

doi:10.1186/s12879-019-4093-1

Table 2 MIC distribution of Eravacycline and relevant antibiotics against E. coli and E. cloacae of different resistance characteristics

From: In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China

Organism	Antibiotics	Carbapenem resistant ^a			ESBL			Sensitive ^b
Organism	Antibiotics	MIC₅₀	MIC₉₀	Range	MIC₅₀	MIC₉₀	Range	MIC₅₀	MIC₉₀	Range
E.coli	Eravacycline	0.5	1	0.064–2	0.125	0.25	0.064–0.25	0.064	0.125	0.064–0.25
	Tigecycline	1	2	0.25–4	0.25	0.5	0.25–0.5	0.25	0.25	0.125–0.5
	Piperacillin/Tazobactam	256	256	2–256	2	8	1–256	1	2	0.5–2
	Cefoxitin	256	256	64–256	8	32	4–32	2	4	2–8
	Ceftazidime	256	256	0.5–256	32	64	16–128	0.064	0.25	0.064–0.25
	Cefoperazone/Sulbactam	256	256	8–256	16	32	8–256	0.25	1	0.064–4
	Ceftriaxone	256	256	2–256	256	256	64–256	0.032	0.064	0.016–0.064
	Cefotaxime	256	256	4–256	256	256	64–256	0.032	0.064	0.032–0.064
	Cefepime	64	256	0.25–256	32	64	8–128	0.016	0.032	0.016–0.064
	Ertapenem	32	32	16–32	0.125	0.25	0.016–1	0.016	0.016	0.016–0.016
	Imipenem	8	32	8–64	0.125	0.125	0.125–1	0.125	0.125	0.064–0.125
	Meropenem	8	32	4–32	0.032	0.064	0.016–0.064	0.016	0.016	0.016–0.016
	Amikacin	4	256	0.5–256	2	4	1–8	2	2	1–4
	Minocycline	8	16	0.5–16	1	8	0.5–16	1	2	0.5–8
	Ciprofloxacin	64	64	0.064–64	32	64	0.25–64	4	32	0.016–32
	Levofloxacin	16	64	0.125–128	16	32	0.5–64	8	8	0.032–16
	Moxifloxacin	16	32	0.5–64	16	32	0.5–64	8	16	0.032–16
E.cloacae	Eravacycline	0.5	0.5	0.5–0.5	0.25	0.5	0.125–0.5	0.5	0.5	0.125–1
	Tigecycline	2	2	2–2	1	1	0.125–2	0.5	2	0.5–2
	Piperacillin/Tazobactam	256	256	256–256	4	4	2–8	2	64	0.5–256
	Cefoxitin	256	256	256–256	8	32	4–256	256	256	64–256
	Ceftazidime	256	256	256–256	16	64	16–256	0.25	64	0.064–256
	Cefoperazone/Sulbactam	32	32	32–32	8	16	4–32	0.125	32	0.016–256
	Ceftriaxone	256	256	256–256	64	128	16–256	0.125	128	0.016–256
	Cefotaxime	256	256	256–256	64	128	16–256	0.125	256	0.016–256
	Cefepime	256	256	256–256	8	8	1–32	0.032	8	0.016–128
	Ertapenem	32	32	32–32	0.032	0.064	0.016–0.125	0.032	0.5	0.016–16
	Imipenem	32	32	32–32	0.25	0.25	0.125–0.25	0.25	1	0.125–2
	Meropenem	32	32	32–32	0.016	0.032	0.016–0.032	0.032	0.064	0.016–4
	Amikacin	256	256	256–256	1	2	1–8	1	2	0.5–256
	Minocycline	4	4	4–4	4	4	2–8	2	4	1–64
	Ciprofloxacin	64	64	64–64	2	32	0.25–64	0.032	4	0.016–64
	Levofloxacin	4	4	4–4	1	8	0.5–16	0.064	4	0.032–16
	Moxifloxacin	8	8	8–8	2	16	1–16	0.125	4	0.032–16

^a: Of the 15 carbapenem resistant E.coli, 5 strains harbored mcr-1 and NDM-5 simultaneously
^b: Sensitive strains referred to strains do not have ESBL and carbapenem resistance

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us